ClinicalTrials.gg
CompletedNCT03165240Updated Sep 20, 2024

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

A Phase 1 interventional study of BI 690517 and Eplerenone in Diabetic Nephropathies, sponsored by Boehringer Ingelheim. Completed at 40 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Diabetic Nephropathies with a site in Spain — none open to participants now, 1 under way, none of them phase 3. Diabetic Nephropathies · Spain.

Enrollment
19th of 20
62 · median 265
Started
2017
the only one that year
Phase 1
Only one
of the 21
Registered
16th of 21
by date
Lead sponsor
3 of 21
Boehringer Ingelheim

Among the 21 studies in Diabetic Nephropathies with a site in Spain, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2017, is the only one in phase 1, and was the 16th registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

None of the 21 studies in Diabetic Nephropathies with a site in Spain is open now. The open studies under Diabetic Nephropathies, anywhere →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Diabetic Nephropathies with a site in Spain as a file.
02

Study summary

The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor blockers [ARB].

Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine Ratio [UACR].

03

Conditions studied

  • Diabetic Nephropathies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  • Male or (last menstruation ≥ 2 years ago) patients, or female patients who are sterilized by either hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy. Male patients with partners of must be willing to use condoms from the time of the first intake of study drug until follow-up.
  • (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 and \< 75 ml/min/1.73 m2 at Visit 1 measured by the central laboratory and no planned start of renal replacement therapy during the trial.
  • UACR ≥ 200 and \<3500 mg/g in spot urine (midstream urine sample) at Visit 1 measured by the central laboratory.
  • Treatment with either ACEi or ARB, stable dose since ≥ 4 weeks before Visit 1 with no planned change of the therapy.
  • Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral antidiabetic medication. Treatment should have been unchanged (investigator's judgment) within 4 weeks before Visit 1 and until randomisation.
  • (HbA1c) \< 10.0% at Visit 1 measured by the central laboratory.
  • Seated SBP ≥ 110 and ≤ 180 mmHg and DBP ≥ 70 and ≤ 110 mmHg at Visit 1
  • Age at screening ≥ 18 years for male and permanently sterilized female patients and ≥ 45 years for postmenopausal female patients.
  • (BMI) ≥ 18.5 and \< 45 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Treatment with with SGLT2 inhibitors and/or inhibitors of aldosterone mediated effects like mineralocorticoid receptor antagonists at visit 1 and thereafter.
  • Intake of potassium sparing diuretics like amiloride or potassium supplements during the study (this period starts at Visit 1).
  • At Visit 1 cortisol peak level 30 minutes (± 5 min) after iv injection of Adrenocorticotropic hormone (ACTH) is an increase by less than 200 nmol/l compared to pre-ACTH injection.
  • Dual or triple blockade of the Renin Angiotensin System (RAS) (e.g. ACEi + ARB; ACEi + renin inhibitor; or ARB + renin inhibitor; or ACEi + ARB + renin inhibitor) 12 weeks before Visit 1 and for the duration of study.
  • History of non-diabetic renal disease according to investigator's opinion and/or renal transplant recipients.
  • Hyperkalaemia (K+ > 5.0 mmol/L) at visit 1 and until start of treatment measured by any local or central lab.
  • Clinical signs of acute or chronic urinary tract infection 14 days before randomization (based on investigator's judgement).
  • Acute febrile diseases 14 days before randomisation (based on investigator´s judgement).
  • Heart failure, patients with III / IV.
  • Surgery or trauma with significant blood loss or blood donation within 12 weeks prior to first administration of study medication (based on investigator´s judgement) or planned surgeries during the trial e.g. hip replacement (based on investigator's judgement).
  • Any other medical condition that in the investigator's opinion poses a safety risk for the patient or may interfere with the study objectives.
  • Any laboratory value more than 3 times above upper limit normal () at screening (visit 1) or any other laboratory value outside the reference range and in the investigator's judgment.
  • Medical history of cancer or treatment for cancer in the last two years prior to Visit 1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, and prostatic cancer of low grade [T1 or T2] is exempted).
  • Previous enrolment in this trial.
  • Currently enrolled in another device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study patient or unlikely to complete the trial.
  • Women of
  • Further exclusion criteria apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    BI 690517 Dose 1

    Drug: BI 690517

  • Experimental
    BI 690517 Dose 2

    Drug: BI 690517

  • Experimental
    BI 690517 Dose 3

    Drug: BI 690517

  • Experimental
    Eplerenone

    Drug: Eplerenone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Film-coated tablet

    Also known as: Vicadrostat

  • Film-coated tablet

  • DrugPlacebo

    Film-coated tablet

06

What researchers measure

Primary outcomes

  1. Percentage of patients with drug related Adverse Events (AEs)

    Time frame: Up to 35 days

Secondary outcomes

  1. Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in morning void urine

    Time frame: Up to 28 days

  2. Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine

    Time frame: Up to 28 days

07

Study locations

40 sites
  • Steno Diabetes Center Copenhagen
    Gentofte, DK-2820, Denmark
  • Kolding Sygehus
    Kolding, DK-6000, Denmark
  • Bispebjerg og Frederiksberg Hospital
    København NV, 2400, Denmark
  • Copenhagen University Hospital, Rigshospitalet
    København Ø, 2100, Denmark
  • HOP d'Angers
    Angers, 49933, France
  • HOP Michallon
    La Tronche, 38700, France
  • HOP Bichat
    Paris, 75018, France
  • HOP la Milétrie
    Poitiers, 86021, France
  • HOP Nord Laënnec
    Saint-Herblain, 44800, France
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Inamed GmbH
    Gauting, 82131, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
  • Univ. Gen. Hosp. of Ioannina
    Ioannina, 45500, Greece
  • Iatriko of Athens Group/ Iatriko of P. Faliro
    P. Faliro, 17562, Greece
  • Iatriko Psychikou
    Psychiko, 11525, Greece
  • University General Hospital of Thessaloniki AHEPA
    Thessaloniki, 54636, Greece
  • Hospital Dr. Nélio Mendonça
    Funchal, 9004-514, Portugal
  • APDP - Associação Protectora dos Diabéticos de Portugal
    Lisboa, 1250-189, Portugal
  • CHULN, EPE - Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Hospital Beatriz Ângelo
    Loures, 2674-514, Portugal
  • Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António
    Porto, 4099-001, Portugal
  • Res.Inst.-Compl.Iss.Cardi.Dis.
    Kemerovo, 650002, Russian Federation
  • City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow
    Moscow, 109263, Russian Federation
  • Nonstate Private Healthcare Institution "Scientific Clinical Center of LLC Russian Railways"
    Moscow, 125315, Russian Federation
  • Baltic Med,LLC Clinic BaltMed Ozerki
    St. Petersburg, 194356, Russian Federation
  • D & R s.r.o.
    Kosice, 040 22, Slovakia
  • Hospital A Coruña
    A Coruña, 15006, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de Bellvitge
    L'Hospitalet de Llobregat, 08907, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Puerta de Hierro
    Majadahonda, 28222, Spain
  • Hospital Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Clínico de Valencia
    Valencia, 46010, Spain
  • CTC Sahlgrenska Universitetssjukhuset
    Göteborg, 413 45, Sweden
  • Sjukhuset, Härnösand
    Härnösand, 871 31, Sweden
  • CTC Clinical Trial Consultants AB
    Uppsala, 75237, Sweden
  • Universitetssjukhuset, Örebro
    Örebro, 701 85, Sweden
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2020, 30 months.

Of 20 phase 1 interventional studies under Diabetic Nephropathies, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
May 24, 2017
StartActual
Oct 5, 2017
Primary completionActual
Apr 16, 2020
CompletionActual
May 7, 2020
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03165240
Responsible party
Sponsor
First posted
May 24, 2017
Start date
Oct 5, 2017
Primary completion
Apr 16, 2020
Completion
May 7, 2020
Last update
Sep 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vicadrostat · Eplerenone

Start the discussion